Cardiometabolic Risk in Type 2 Diabetes: What Can the PPAR-g Agonists Teach Us?

1
Cardiometabolic Risk in Type 2 Diabetes What
Can the PPAR-g Agonists Teach Us?
2
UKPDS 35 Impact of Increasing A1c on
Cardiovascular Disease in T2DM
3
Insulin Resistance Is Associated With or Directly
Responsible for Factors Causing Atherothrombosis
4
UKPDS 35 Effect of A1c on MI and Microvascular
Events
5
UKPDS 80 10-Year Follow-up Study of Intensive
Glycemic Control in T2DM
6
Incidence of CV Events in Subjects With T2DM vs
the Nondiabetic CAD Population
7
PPAR-g Agonists Lipoprotein Effects
8
PROactive Time to Secondary CV Composite End
Point
9
FDA Statistical Review and Evaluation
Meta-analysis of Pioglitazone
10
CV Events With PPAR-g Agonists
11
Genes Uniquely Regulated by the TZDs
12
Pioglitazone Induces IkBa Protein Expression In
Vivo in a PPAR-a-Dependent Manner
13
The Concept of Dual PPAR-a/g Agonists
14
Effect of Muraglitazar on Composite CV Endpoints
15
Effect of Tesaglitazar on Serum Creatinine and
Glomerular Filtration
16
SYNCHRONY Effect of Aleglitazar vs Pioglitazone
on A1c
17
SYNCHRONY Effect of Aleglitazar vs Pioglitazone
on LDL-C and HDL-C
18
ALECARDIO Aleglitazar in Patients With T2DM and
ACS
19
Program Summary
20
(No Transcript)
21
(No Transcript)
22
(No Transcript)